Research Paper Volume 11, Issue 7 pp 2138—2150

MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway

Figure 3. miR-204 targets CAV-1 in NSCLC. (A) Seed region of the CAV-1 3′ UTR paired with miR-204. (B) Expression of miR-204 in A549, CR-A549, PC9, and CR-PC9 cell lines. *P<0.05. (C) Transfection efficiency of miR-204 in CR-A549 and CR-PC9 cells. *P<0.05 vs. NCO group. (D) Effect of miR-204 (50 pmol/ml) on the expression level of CAV-1 in CR-A549 and CR-PC9 cells. (E) Luciferase activities in CR-A549 and CR-PC9 cells were measured using the Dual-Luciferase Reporter Assay System. *P<0.05 vs. NCO group.